LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | PD0325901 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 2557 | 3970 | 0.6440 | 0.4638 |
| BT-20 | PD0325901 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2322 | 3970 | 0.5849 | 0.3748 |
| BT-20 | PD173074 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2948 | 3970 | 0.7426 | 0.6122 |
| BT-20 | PD184352 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1519 | 3970 | 0.3826 | 0.0700 |
| BT-20 | Pelitinib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 591 | 3970 | 0.1489 | -0.2820 |
| BT-20 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 571 | 3970 | 0.1438 | -0.2897 |
| BT-20 | PF477736 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1264 | 3970 | 0.3184 | -0.0267 |
| BT-20 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 812 | 3970 | 0.2045 | -0.1983 |
| BT-20 | PHA-665752 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1692 | 3970 | 0.4261 | 0.1355 |
| BT-20 | PHA-793887 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 689 | 3970 | 0.1737 | -0.2447 |
| BT-20 | PI103 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 1039 | 3970 | 0.2617 | -0.1122 |
| BT-20 | PLX-4720 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 2460 | 3970 | 0.6195 | 0.4269 |
| BT-20 | QL-X-138 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 836 | 3970 | 0.2105 | -0.1892 |
| BT-20 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 837 | 3970 | 0.2108 | -0.1888 |
| BT-20 | Radicicol | 10.0 | uM | LJP5 | 72 | hr | 1334 | 967 | 3970 | 0.2436 | -0.1393 |
| BT-20 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1334 | 983 | 3970 | 0.2476 | -0.1333 |
| BT-20 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1724 | 3970 | 0.4342 | 0.1478 |
| BT-20 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 3058 | 3970 | 0.7703 | 0.6540 |
| BT-20 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1451 | 3970 | 0.3655 | 0.0443 |
| BT-20 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2063 | 3970 | 0.5195 | 0.2763 |
| BT-20 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 4027 | 3970 | 1.0142 | 1.0214 |
| BT-20 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2748 | 3970 | 0.6922 | 0.5364 |
| BT-20 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 3352 | 3970 | 0.8441 | 0.7652 |
| BT-20 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1289 | 3970 | 0.3246 | -0.0173 |
| BT-20 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 842 | 3970 | 0.2120 | -0.1869 |